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Abstract
Background: Cardiovascular-related deaths account for nearly 30% of deaths worldwide. Age, diabetes
mellitus, the male gender, and use of tobacco products have been identified as risk factors in previous studies;
however, most recent research is directing attention toward other causes of cardiovascular-related mortality.
Parathyroid hormone (PTH), an important component in the maintenance of mineral homeostasis, has
shown to be linked to cardiovascular events when the levels are high. As a result, it becomes fundamental to
seek the relationship between elevated levels of PTH in a generally healthy population aged 50 and older and
cardiovascular-related mortality.
Methods: An exhaustive literature search was conducted using the following search engines: Medline-OVID,
Web of Science, and CINAHL. For each literature search, the key words parathyroid hormone, cardiovascular,
mortality, and adult were utilized to narrow the results. The following inclusion criteria were required in
narrowing the search: studies including adults aged 50 and older, studies that measure cardiovascular-related
mortality as the primary outcome, studies that investigate elevated PTH in generally healthy populations, and
studies with a mean follow-up of at least seven years. Similarly, the following exclusion criteria were applied to
the search: studies published before the year 2009, studies not performed on humans, and studies in a
language other than English. All articles were assessed for quality using GRADE.
Results: The search resulted in 156 articles, all of which were viewed for relevancy. After the application of
inclusion and exclusion criteria, two community-based cohort studies were included. Both observational
studies demonstrated a position correlation between increased parathyroid hormone and cardiovascular
mortality in community-dwelling adults over the age of 50. The primary outcome measured was
cardiovascular mortality, and no other surrogate outcomes were used. After the GRADE assessment, both
prospective cohort studies were considered to be low quality.
Conclusion: Two observational studies show a correlation between high parathyroid hormone and
cardiovascular-related mortality in populations of generally healthy community-dwelling adults. At this time,
the low quality evidence is not enough to support the correlation. However, due to these findings, future
studies may possibly confirm use parathyroid hormone as a modifiable risk factor in the prevention of
cardiovascular-related mortality.
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Abstract   
 
Background: Cardiovascular-related deaths account for nearly 30% of deaths worldwide. Age, 
diabetes mellitus, the male gender, and use of tobacco products have been identified as risk 
factors in previous studies; however, most recent research is directing attention toward other 
causes of cardiovascular-related mortality. Parathyroid hormone (PTH), an important component 
in the maintenance of mineral homeostasis, has shown to be linked to cardiovascular events 
when the levels are high. As a result, it becomes fundamental to seek the relationship between 
elevated levels of PTH in a generally healthy population aged 50 and older and cardiovascular-
related mortality. 
 
Methods:  An exhaustive literature search was conducted using the following search engines: 
Medline-OVID, Web of Science, and CINAHL. For each literature search, the key words 
parathyroid hormone, cardiovascular, mortality, and adult were utilized to narrow the results. 
The following inclusion criteria were required in narrowing the search: studies including adults 
aged 50 and older, studies that measure cardiovascular-related mortality as the primary outcome, 
studies that investigate elevated PTH in generally healthy populations, and studies with a mean 
follow-up of at least seven years. Similarly, the following exclusion criteria were applied to the 
search: studies published before the year 2009, studies not performed on humans, and studies in 
a language other than English. All articles were assessed for quality using GRADE. 
 
Results: The search resulted in 156 articles, all of which were viewed for relevancy. After the 
application of inclusion and exclusion criteria, two community-based cohort studies were 
included. Both observational studies demonstrated a position correlation between increased 
parathyroid hormone and cardiovascular mortality in community-dwelling adults over the age of 
50. The primary outcome measured was cardiovascular mortality, and no other surrogate 
outcomes were used. After the GRADE assessment, both prospective cohort studies were 
considered to be low quality. 
 
Conclusion: Two observational studies show a correlation between high parathyroid hormone 
and cardiovascular-related mortality in populations of generally healthy community-dwelling 
adults. At this time, the low quality evidence is not enough to support the correlation. However, 
due to these findings, future studies may possibly confirm use parathyroid hormone as a 
modifiable risk factor in the prevention of cardiovascular-related mortality. 
 
Keywords: Parathyroid hormone, cardiovascular, mortality, and adult 
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BACKGROUND 
 Approximately 30% of deaths worldwide and nearly 40% of deaths in high-income 
countries can be attributed to cardiovascular-related causes.1 Factors including the male gender, 
reduced HDL cholesterol levels, use of tobacco products, age, and diabetes mellitus have been 
shown to increase risk of cardiovascular-related mortality; however, further research has begun 
to point toward other potential causes.2 Parathyroid hormone (PTH), a key regulator in the 
homeostasis of magnesium, calcium and phosphate levels, has the ability to result in 
cardiovascular-related events when elevated or diminished levels are present.3 Since 
approximately 9-15% of females and a slightly lower level of males in the United States adult 
population have some type of thyroid disease, this phenomenon becomes of vital importance to 
investigate.3,4 
There have been several studies that have conveyed a positive correlation between high 
levels of PTH and cardiovascular-related mortality in Chronic Kidney Disease (CKD) patients, 
which have resulted due to a mineral imbalance.4 Similarly, another study noted that PTH levels 
above 65 pg/mL in healthy members of a population increases their risk for heart failure by 30% 
(95% CI: 6% to 61%).5 With history of this evidence, placing emphasis on research in generally 
healthy community-based populations will help establish a new framework behind the function 
of PTH and encompass an expanded group of individuals. Although the effects of high PTH have 
been researched regarding cardiovascular events, the rate of cardiovascular-related mortality 
should be further explored.  
Additionally, another prospective cohort study6 revealed that PTH receptors are located 
body wide, which indicates the potential of PTH to affect the nervous, skeletal, cardiac, and renal 
systems, potentially leading to cardiovascular disease (CVD) risk and mortality. By inspecting 
the mechanism of action regarding high PTH, further research can be performed to develop an 
understanding of the systematic effects on the body. Specifically, activation of the renin-
angiotensin-aldosterone system (RAAS) results in cardiac remodeling and high blood pressure. 
Elevated PTH induces hardening of the arteries and vascular inflammation.6 By increasing levels 
of calcium within the cells, a natural response of elevated PTH, left ventricular hypertrophy and 
calcification of the heart valves can occur.5 Overall, these mechanisms serve as a basis in 
understanding the role in cardiovascular-related mortality.  
By identifying risk factors, such as elevated PTH, in patients within clinic, it becomes 
more reasonable and measureable to monitor and prevent complications. With the potential of 
elevated PTH having public health implications, identifying it as a risk factor is of vital 
importance in early detection of cardiovascular risks. For the reasons mentioned above, it 
becomes fundamental to seek the relationship between elevated levels of PTH in a generally 
healthy population aged 50 and older and cardiovascular-related mortality. 
METHODS 
An exhaustive literature search was conducted using the following search engines: 
Medline-OVID, Web of Science, and CINAHL. For each literature search, the key words 
parathyroid hormone, cardiovascular, mortality, and adult were utilized to narrow the results. 
The following inclusion criteria were required in narrowing the search: (1) studies including 
adults aged 50 and older, (2) studies that measure cardiovascular-related mortality as the primary 
outcome, (3) studies that investigate elevated PTH in generally healthy populations, and (4) 
studies with a mean follow-up of at least seven years. Similarly, the following exclusion criteria 
were applied to the search: (1) studies published before the year 2009, (2) studies not performed 
on humans, and (3) studies in a language other than English. After application of inclusion and 
exclusion criteria to determine applicability, the GRADE system served to assess the quality of 
each remaining study.7 
RESULTS 
 The search resulted in 22 articles via Medline-OVID, 119 via Web of Science, and 15 via 
CINAHL, for a total of 156 articles. These articles were all reviewed and screened for relevancy 
by use of the inclusion and exclusion criteria, which resulted in the utilization of two cohort 
studies.6,8 
Ballegooijen et al 
 This prospective cohort study6 sought to investigate elevated PTH levels and its 
association with cardiovascular-related mortality in a general population. A total of 633 
participants were included in the study, with an average age of 70.1 ± 6.6 years. Initially, the first 
group of individuals invited to participate in the study were those with impaired glucose levels 
(n=193), diabetes type 2 (n=176), and normal glucose levels (n=705). Only 648 of these 
individuals decided to participate. An additional 188 people with type 2 diabetes were invited to 
participate. However, those without serum PTH values were excluded from the study. Ingestion 
of lithium medication was also considered exclusion criteria, since calcium levels may be 
altered. The specific selection methodology was not mentioned. Overall, the primary outcomes 
of the study were cardiovascular mortality and all-cause mortality, which were categorized by 
the use of International Classification of Diseases (ICD) codes 390 to 459 (circulatory system 
diseases) or 798 (sudden death).6 
 After the application of eligibility criteria, baseline measurements, demographics, 
lifestyle habits, dietary variables, metabolic variables, and cardiac measures were recorded for 
each participating individual and utilized to maintain prognostic balance throughout the study. 
These groups demonstrated prognostic balance. PTH quartiles were also created to seasonally 
classify the results, with the lower three quartiles serving as a reference group. Since vitamin D 
levels fluctuate depending on the level of sun exposure, classifying the information into seasonal 
groups will eliminate a potential confounding variable. Statistical results were also adjusted for 
age, gender, level of education, systolic blood pressure (SBP), use of tobacco products, BMI, 
GFR, microalbuminuria, and use of antihypertensive medications. By using Kaplan-Meier 
analysis, the differences in survival between the four PTH quartiles were represented 
graphically.6 
 After a median follow-up of 7.8 years, 18% of participants died (n=112), and 23% of the 
deaths (n=26) were determined to be cardiovascular-related. The Kaplan-Meier curve illustrated 
a significantly decreased survival in quartile 4, which had the highest PTH levels (P=0.022). By 
using a threshold model where the three lowest quartiles are used as a reference group (quartile 4 
versus quartile 1-3), there was a significant association between cardiovascular-related mortality 
and high PTH; HR =2.56 (1.11, 5.94; P=0.028).6 
Hagstrom et al 
 This prospective cohort study8 sought to investigate the risk of cardiovascular mortality 
in relation to high PTH in the community. Initially, 1221 individuals were invited to complete a 
health survey, which identified cardiovascular-related risk factors. Of these participants, a total 
of 958 were included in the study because their PTH measurements were valid. However, the 
specific methodology for selecting these individuals is not mentioned. The average age of the 
participants was 71. To further rule out confounding variables, the final group was analyzed in 
several subgroups: (1) those without previous CVD (n=617), (2) those with a PTH level in the 
normal range (<6.8 pmol/L; n=868), and (3) those with normal levels of calcium (2.2 to 2.6 
mmol/L), GFR (>50 mL x min-1 x 1.73 m-2), and vitamin D levels (>37.5 nmol/L; n=646). 
Overall, the primary outcomes of the study were cardiovascular mortality and all-cause 
mortality, which were categorized by the use of ICD-9 codes 390 to 459 or ICD-10 codes 100-
199.8 
 After all participants gave written consent, baseline measurements, demographics, 
lifestyle habits, dietary variables, metabolic variables, and cardiac measures were recorded for 
each participating individual and utilized to maintain prognostic balance throughout the study. 
There was prognostic balance with these demographics. Specifically, statistical results were 
adjusted for age, SBP, BMI, use of tobacco products, diabetes mellitus, HDL cholesterol, use of 
antihypertensive or lipid-lowering medications, and history of CVD.8 
 After a median follow-up of 9.7 years (1.2 to 12.4), a total of 277 individuals died. Of 
those 277 participants, 117 can be attributed to cardiovascular-related causes. When considering 
the entire sample size, there was a 37% to 38% higher cardiovascular-related mortality risk for 
every 1-SD rise in PTH. After accounting for previous cardiovascular risk factors as mentioned 
above, cardiovascular-related mortality showed to be associated with high PTH (HR: 1.39, 95% 
CI, 1.18 to 1.60; P<0.001). Regarding the subgroups (those without previous CVD, those with 
normal PTH, and those with normal mineral metabolism), there remained an association between 
high PTH and cardiovascular-related mortality. Overall, high PTH (>5.27 pmol/L) accounted for 
20% (95% CI, 10 to 26) of the cardiovascular-related deaths.8 
DISCUSSION 
 After careful review of the selected articles,6,8 the data revealed a positive relationship 
between increased PTH and its link to cardiovascular-related mortality in generally healthy 
populations with individuals aged 50 and older. As mentioned previously, PTH is a key 
regulatory hormone in the balance of calcium, phosphate, and vitamin D and in maintaining 
homeostasis.10 When performing research on this relationship, it becomes important to 
distinguish one variable from the next. Seemingly, the diagnostic utility and use of serum PTH as 
a prognostic marker for chronic disease is increasing through the use of measuring other 
circulating PTH molecular forms. These fragment-specific samples will aid in the understanding 
of mineral homeostasis.11 Regarding future research, this approach may be a helpful link in 
unravelling the complex relationship of these minerals, further helping to establish the role of 
PTH and adjust for potential confounders. One prospective cohort study12 has attempted to 
research the relationship of all key metabolites and minerals involved in PTH, although more 
research is needed.12 Similarly, another prospective cohort study13 investigated the impact of 
fibroblast growth factor 23 and its impact on the incidence of cardiovascular mortality due to its 
role in mineral metabolism.13 Once these complex relationships begins to unravel, the potential 
for PTH to become a modifiable risk factor is more realistic for future clinical practice. The 
differentiation between various ethnic groups will also help determine the role of PTH.14 
Despite the positive correlation between cardiovascular-related death and high PTH in 
the Ballegooijen et al study6, there are several limitations that restrict complete confirmation of 
that data. Since this study6 is a prospective cohort study, the reliability of the design limits trust 
in the outcomes. Additionally, there was a relatively low number of cardiovascular-related deaths 
(n=26). Although the study also intended to exclude the use of medications that would affect 
mineral metabolism, there was missing information about the utilization of bisphosphonates. 
Similarly, there was missing information on calcium and phosphate levels, which would have 
been impacted by the use of bisphosphonates.6 Considering these faults, it becomes difficult to 
use this data with full trust in the methodology behind the study. Lastly, there was a single PTH 
measurement at the beginning of the study, and additional samples were not taken throughout the 
years. Essentially, this is putting reliance on that idea that one baseline value has the potential to 
define consequences which are to follow years later. Since there has been no solid statistical 
evidence behind this strategy, it becomes questionable for whether or not this is the most 
effective approach.6 
 Although the Hagstrom et al study8 also determined there was a positive correlation 
between elevated PTH and cardiovascular-related mortality (in fact there appears to be a dose-
response gradient in that as PTH levels increase so do mortality rates), there are several 
limitations that should be considered. Due to the fact that this is a prospective cohort study, the 
quality of the study is already significantly diminished to low. Additionally, this study8 focused 
on elderly men instead of the entire population. This makes the resulting data less generalizable 
to the community as a whole. Lastly, there was a single PTH measurement at the beginning of 
the study with no other measurements taken throughout the expanse of the research. As 
mentioned previously, there is no statistical evidence behind this approach, and there exists 
uncertainty in the effectiveness of the methodology.  
 Overall, future research is needed to enhance the understanding between PTH and 
cardiovascular-related mortality. Specifically, research should focus on deciphering whether or 
not PTH levels or other minerals such as calcium, phosphate, or vitamin D levels are the primary 
concerning factor. Furthermore, research evaluating whether or not PTH levels can be 
manipulated and how this alteration can benefit patients is of great interest. To determine the 
utility of PTH in a risk assessment for evaluating chronic disease would be of utmost usefulness 
in patient evaluation. 
CONCLUSION 
 As a result of this systematic review, the two reviewed studies showed a correlation 
between high PTH and increased risk of cardiovascular-related mortality in generally healthy 
community-based populations. Although PTH can easily be considered its own entity, it 
intertwines complexly with other minerals in the body. Its role with calcium, phosphate, and 
vitamin D make it difficult to disentangle the relationship and study each component separately.9 
As a result, distinguishing each individual component becomes complex and needs further 
refinement in future studies. The need for randomized control trials in future studies also 
becomes of utmost interest to gain quality evidence behind these theories. Overall, it seems that 
the role of the relationship between elevated PTH and cardiovascular-related mortality in the 
generally healthy population is crucial to identifying key modifiable risk factors. Through further 
investigation, using PTH serum levels as a predictor of cardiovascular risk has the potential to 
become an important part of the future of healthcare. 
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Characteristics of Reviewed Studies 
 
Table I. van Ballegooijen et al6 and Hagstrom et al8 
Quality Assessment  
 Downgrade Criteria  
Study Design Limitations Indirectness Imprecision Inconsistency Publication 
bias likely 
Quality 
Parathyroid Hormone Low 
Van 
Ballegooijen 
et al 
Cohort Not serious Not serious Not serious Not serious No Low 
Hagstrom et 
al 
Cohort Not serious Not serious Not serious Not serious No Low 
 
 
Summary of Findings 
 
Table II. van Ballegooijen et al6 
 Baseline Cardiovascular Mortality (median follow-up 
of 7.8 years) 
P-value for 
trend 
Group (n = 633) Mean Serum PTH (min, 
max) in pmol/L 
Events (n = 26) HR, 95% CI (min, max)  
Quartile 1 (n = 156) 3.9 (1.7, 4.8) 4 Reference 0.121 
Quartile 2 (n = 158) 5.2 (4.3, 6.0) 5 1.23 (0.32, 4.64)  
Quartile 3 (n = 160) 6.3 (5.4, 7.3) 4 0.82 (0.20, 3.30)  
Quartile 4 (n = 159) 9.4 (6.6, 33.8) 13 2.58 (0.79, 8.36)  
 
 
Table III. Hagstrom et al8 
 Baseline Cardiovascular Mortality (median follow-up 
of 9.7 years) 
P-value 
Group (n = 958) Mean Serum PTH in 
pmol/L 
Events (n = 117) HR, 95% CI (min, max)  
Quartile 1 <2.96 Unknown Reference >0.05 
Quartile 2 2.96-3.99 Unknown 0.78 (0.43, 1.43) >0.05 
Quartile 3 4.00-5.27 Unknown 0.99 (0.56, 1.72) >0.05 
Quartile 4 >5.27 23 1.83 (1.10, 3.04) <0.05 
 
 
 
 
 
 
 
